# PRODUCT INFORMATION



# O-Desmethyl Gefitinib

Item No. 22365

CAS Registry No.: 847949-49-9

Formal Name: 4-[(3-chloro-4-fluorophenyl)

amino]-6-[3-(4-morpholinyl)

propoxy]-7-quinazolinol

C<sub>21</sub>H<sub>22</sub>CIFN<sub>4</sub>O<sub>3</sub> MF:

432.9 FW: ≥95% **Purity:** Supplied as: A solid Storage: -20°C Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

# Description

O-Desmethyl gefitinib is the major metabolite of gefitinib (Item No. 13166) in human plasma, formed by the cytochrome P450 isoform CYP2D6.1 It is an active metabolite that inhibits EGFR similarly to gefitinib in subcellular assays ( $IC_{50}s = 36$  and 22 nM, respectively) but is less active in whole cell assays ( $IC_{50}s = 760$  and 49 nM, respectively).<sup>2</sup> In a LoVo tumor mouse xenograft model, the tumor concentration of O-desmethyl gefitinib was 6.8-fold lower than that of gefitinib and did not significantly reduce tumor growth. A high plasma concentration of O-desmethyl gefitinib in patients homozygous for CYP2D6 was not associated with an increase in adverse effects.3

## References

- 1. McKillop, D., Hutchison, M., Partridge, E.A., et al. Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. Xenobiotica 34(10), 917-934 (2004).
- 2. McKillop, D., Guy, S.P., Spence, M.P., et al. Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition. Xenobiotica 36(1), 29-39 (2006).
- 3. Kobayashi, H., Sato, K., Niioka, T., et al. Effects of polymorphisms in CYP2D6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib. Med. Oncol. 33(6), 1-8 (2016).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

### WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 10/26/2022

# **CAYMAN CHEMICAL**

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM